Update on ONCONASE Clinical Program

Source: Alfacell Corp
January 19, 2006

BLOOMFIELD, N.J., Jan. 19 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) today announced that over 300 patients are now enrolled in the Company's international, confirmatory Phase IIIb trial evaluating ONCONASE® (ranpirnase), the Company's lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM). The required number of patients for full enrollment is 316. The Company will continue to provide updates as key developments occur.

"We have been unwavering in our commitment to complete the ONCONASE UMM clinical program," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "In enrolling more than 300 patients, Alfacell is conducting one of the largest global UMM studies ever undertaken. We now look forward to achieving more milestones on our regulatory path towards bringing ONCONASE to market."

About Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC).

More on chemotherapy for mesothelioma.